Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Earnings drop 52% in the quarter and 58% for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer

4Q Revenues: $13.1 billion (-3%)

4Q Earnings: $1.2 billion (-52%)

FY Revenues: $49.6 billion (-4%)

FY Earnings: $9.1 billion (-58%)

Comments: Global vaccine sales were up 22% in the quarter to $1.3 billion. Consumer healthcare sales were up 4% to $953 million. Global oncology sales were $609 million, up 10%. Established product sales were down 7%, due to declining Lipitor sales in developed markets, the loss of exclusivity for Celebrex and Detrol LA in the U.S., and Aricept in Canada. Innovative Product sales were up 6% driven by Lyrica and recently launched products, including Eliquis globally and Xeljanz, primarily in the U.S. Revenues in emerging markets increased 7%, driven by Lipitor, primarily in China, as well as Prevenar and Enbrel. This was offset primarily by generic competition for Celebrex, the expiration of the co-promotion term for Enbrel in the U.S. and Canada, the termination of the Spiriva collaboration in certain countries, as well as other product exclusivity losses in certain markets. Results in the quarter include an unfavorable impact of foreign exchange of $449 million, or 3%. R&D expenses were up 15% to $2.0 billion in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters